Person with cancer—lung cancer immunohistochemistry type, code N[N]

Identifying and definitional attributes

Metadata item type:Data Element
Short name:Lung cancer immunohistochemistry
METeOR identifier:433027
Registration status:Health, Standard 08/05/2014
Definition:The type of immunohistochemistry stains used to assist in the identification of abnormal cells and hence the diagnosis of a person with cancer, as represented by a code.
Context:This should be collected for people with cancer where pathology data is available.
Data Element Concept:Person with cancer—immunohistochemistry type

Value domain attributes

Representational attributes

Representation class:Code
Data type:Number
Format:N[N]
Maximum character length:2
Permissible values:
ValueMeaning
1Thyroid transcription factor-1 (TTF-1)
2Cytokeratin 5 (CK5)
3Cytokeratin 6 (CK6)
4Cytokeratin 7 (CK7)
5Cytokeratin 20 (CK20)
6p53-related transcription factor p63 (p63)
7Napsin
88Other
Supplementary values:
97Not applicable-immunohistochemical staining not performed
98Unknown if imunohistochemistry performed
99Immunohistochemistry performed but stains not stated/inadequately described

Collection and usage attributes

Guide for use:Record the code for each immunohistochemical profile obtained to assist in the diagnosis of lung cancer.
Comments:

Thyroid transcription factor-1 and cytokeratin 7 and 20 can be useful, in conjunction with tumour morphology and clinical and radiological findings, to help to distinguish between primary and metastatic lung adenocarcinomas.

Cytokeratin 5/6 and p63 immunostaining is used by some pathologists to help to determine whether a tumour is a squamous or non-squamous type.

The majority (about 75%) of primary lung adenocarcinomas are CK7 positive, CK20 negative and TTF-1 positive and Napsin stains are positive in approximately 80% of of primary lung adenocarcinomas.

Source and reference attributes

Submitting organisation:Cancer Australia
Reference documents:Royal College of Pathologists of Australasia 2010. Lung cancer structured reporting protocol. 1st Edition (Version 1.0). Surry Hills, NSW: Royal College of Pathologists of Australasia

Data element attributes

Collection and usage attributes

Guide for use:

Record each immunohistochemical profile obtained to assist in the diagnosis of cancer.

When "other" is recorded, record the immunohistochemistry stain in text in Person with cancer—immunohistochemistry type, text X[49].
Collection methods:This information should be sought from the patient's medical record and may be included as a supplementary report in the original pathology report, or a stand-alone pathology report if a different laboratory performs the test.
Comments:Immunohistochemistry may be helpful in some instances for precise histological subclassification of the tumour and the exclusion of metastasis.

Source and reference attributes

Submitting organisation:Cancer Australia

Relational attributes

Related metadata references:

See also Person with cancer—immunohistochemistry type, text X[X(49)] Health, Standard 08/05/2014

Implementation in Data Set Specifications:
All attributes +

Lung cancer (clinical) DSS Health, Superseded 14/05/2015

DSS specific attributes +

Lung cancer (clinical) NBPDS Health, Standard 14/05/2015

DSS specific attributes +